Back to top
more

Ekso Bionics Holdings, Inc. (EKSO)

(Delayed Data from NSDQ)

$5.18 USD

5.18
94,586

+0.16 (3.19%)

Updated May 14, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Moving Average Crossover Alert: Ekso Bionics (EKSO)

Ekso Bionics (EKSO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

New Strong Sell Stocks for May 5th

BLKB, CTXS, EKSO, FHI, and GCI have been added to the Zacks Rank #5 (Strong Sell) List on May 5, 2021

Will Ekso Bionics (EKSO) Report Negative Q1 Earnings? What You Should Know

Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekso Bionics (EKSO) Surges 9.4%: Is This an Indication of Further Gains?

Ekso Bionics (EKSO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 0.00% and 22.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?

Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.

What Makes Ekso Bionics (EKSO) a New Buy Stock

Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -25.00% and -9.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -22.22% and -10.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

Kaibalya Pravo Dey headshot

Ekso Bionics (EKSO) in Focus: Stock Moves 6.6% Higher

Ekso Bionics (EKSO) shares rose nearly 7% in the last trading session, amid huge volumes.

Options Traders Expect Huge Moves in Ekso Bionics (EKSO) Stock

Ekso Bionics (EKSO) needs investors to pay close attention to the stock based on moves in the options market lately.

Can The Uptrend Continue for Ekso Bionics Holdings (EKSO)?

Investors certainly have to be happy with Ekso Bionics Holdings, Inc. (EKSO) and its short term performance

Why Trump Could Still Be a Threat to Medical Device Stocks

The Republican healthcare bill, American Health Care Act (ACHA), which was released earlier this month with the target to repeal the Affordable Care Act (ACA), hasn't found favor with the masses.